{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:53:54Z","timestamp":1781690034414,"version":"3.54.5"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"statutory funds of the Maj Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00853-7","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:16:16Z","timestamp":1775546176000},"page":"666-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glutathione deficiency in the early postnatal developmental period as a neurodevelopmental animal model of schizophrenia"],"prefix":"10.1007","volume":"78","author":[{"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"W\u0105sik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"DA Lewis","year":"2000","unstructured":"Lewis DA, Lieberman JA. Caching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325\u201334.","journal-title":"Neuron"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/070674370204700904","volume":"47","author":"EM Goldner","year":"2002","unstructured":"Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002;47:833\u201343.","journal-title":"Can J Psychiatry"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4001563","volume":"10","author":"CA Tamminga","year":"2005","unstructured":"Tamminga CA, Holcomb H. Phenotype of schizophrenia: A review and formulation. Mol Psychiatry. 2005;10:27\u201339.","journal-title":"Mol Psychiatry"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","volume":"90","author":"RR Conley","year":"2007","unstructured":"Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90:186\u201397.","journal-title":"Schizophr Res"},{"issue":"4","key":"853_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132","volume":"108","author":"G Reine","year":"2003","unstructured":"Reine G, Lan\u00e7on C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003;108(4):297\u2013303. https:\/\/doi.org\/10.1034\/j.1600-0447.2003.00132.","journal-title":"Acta Psychiatr Scand"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","volume":"34","author":"BP van Os, Rutten","year":"2008","unstructured":"van Os, Rutten BP, Poulton R. Gene-environment interaction in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull. 2008;34:1066\u201382.","journal-title":"Schizophr Bull"},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijdevneu.2010.10.003","volume":"29","author":"JL Rapoport","year":"2011","unstructured":"Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci. 2011;29:251\u201358.","journal-title":"Int J Dev Neurosci"},{"issue":"22","key":"853_CR8","doi-asserted-by":"publisher","first-page":"11139","DOI":"10.3390\/ijms262211139","volume":"26","author":"M Trubalski","year":"2025","unstructured":"Trubalski M, Markiewicz-Gospodarek A, \u017berebiec M, Poleszak J, Szczotka M, et al. Oxidative stress-mediated neuroinflammation in the pathophysiology of schizophrenia. Int J Mol Sci. 2025;26(22):11139. https:\/\/doi.org\/10.3390\/ijms262211139.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"853_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.nbd.2007.03.001","volume":"26","author":"JH Cabungcal","year":"2007","unstructured":"Cabungcal JH, Preissmann D, Delseth C, Cu\u00e9nod M, Do KQ, Schenk F. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol Dis. 2007;26(3):634\u201345. https:\/\/doi.org\/10.1016\/j.nbd.2007.03.001.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"853_CR10","first-page":"1476","volume":"148","author":"KL Davis","year":"1991","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1476\u201386.","journal-title":"Am J Psychiatry"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","volume":"26","author":"J Coyle","year":"2006","unstructured":"Coyle J. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26:365\u201384.","journal-title":"Cell Mol Neurobiol"},{"key":"853_CR12","first-page":"1","volume":"45","author":"A Grace","year":"2018","unstructured":"Grace A, Gomes FV. The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophr Bull. 2018;45:1\u201310.","journal-title":"Schizophr Bull"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29:97\u2013115.","journal-title":"J Psychopharmacol"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15\u201333.","journal-title":"World Psychiatry"},{"key":"853_CR15","first-page":"4","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropharmacology. 2012;37:4\u201315.","journal-title":"Neuropharmacology"},{"issue":"1","key":"853_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/096032718800700102","volume":"7","author":"B Halliwell","year":"1988","unstructured":"Halliwell B, Gutteridge JM. Free radicals and antioxidant protection: mechanisms and significance in toxicology and disease. Hum Toxicol. 1988;7(1):7\u201313. https:\/\/doi.org\/10.1177\/096032718800700102.","journal-title":"Hum Toxicol"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fpsyt.2019.00093","volume":"10","author":"CH Lin","year":"2019","unstructured":"Lin CH, Lane HY. Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress. Front Psychiatry. 2019;10:93. https:\/\/doi.org\/10.3389\/fpsyt.2019.00093.","journal-title":"Front Psychiatry"},{"issue":"5","key":"853_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","volume":"31","author":"JE Lisman","year":"2008","unstructured":"Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008;31(5):234\u201342. https:\/\/doi.org\/10.1016\/j.tins.2008.02.005.","journal-title":"Trends Neurosci"},{"key":"853_CR19","doi-asserted-by":"publisher","unstructured":"Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative stress-related mechanisms in schizophrenia pathogenesis and new treatment perspectives. Oxid Med Cell Longev. 2021;8881770. https:\/\/doi.org\/10.1155\/2021\/8881770.","DOI":"10.1155\/2021\/8881770"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/1531-8249(200010)48:4<556:AID-ANA2>3.0.CO;2-2.042","volume":"48","author":"GD Pearlson","year":"2000","unstructured":"Pearlson GD. Neurobiology of schizophrenia. Ann Neurol. 2000;48:556\u201366. https:\/\/doi.org\/10.1002\/1531-8249(200010)48:4%26lt;556:AID-ANA2%26gt;3.0.CO;2-2.042.","journal-title":"Ann Neurol"},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","volume":"72","author":"KH Nuechterlein","year":"2004","unstructured":"Nuechterlein KH, Barch D, Gold JM, Goldberg TE, Green MF, Heaton R. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29\u201339. https:\/\/doi.org\/10.1016\/j.schres.2004.09.007.","journal-title":"Schizophr Res"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57\u201373.","journal-title":"Psychopharmacology"},{"key":"853_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","volume":"27","author":"MA Geyer","year":"2003","unstructured":"Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1071\u201379. https:\/\/doi.org\/10.1016\/j.pnpbp.2003.09.003.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"23","key":"853_CR24","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.3390\/molecules242342532","volume":"24","author":"M G\u00f3rny","year":"2019","unstructured":"G\u00f3rny M, Wnuk A, Kami\u0144ska A, Kami\u0144ska K, Chwatko G, et al. Glutathione deficiency and alternations in the sulfur amino acid homeostasis during early postnatal development as potential triggering factor for schizophrenia-like behavior in adult rats. Molecules. 2019;24(23):4253. https:\/\/doi.org\/10.3390\/molecules242342532.","journal-title":"Molecules"},{"issue":"6","key":"853_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/antiox9060538","volume":"19","author":"M G\u00f3rny","year":"2020","unstructured":"G\u00f3rny M, Bilska-Wilkosz A, Iciek M, Hereta M, Kami\u0144ska K, et al. Alterations in the antioxidant enzymes activities in the neurodevelopmental rat model of schizophrenia induced by glutathione deficiency during early postnatal life. Antioxid (Basil). 2020;19(6):538. https:\/\/doi.org\/10.3390\/antiox9060538.","journal-title":"Antioxid (Basil)"},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/jnr.10439","volume":"70","author":"M Rougemont","year":"2002","unstructured":"Rougemont M, Do KQ, Castagn\u00e9 V. New model of glutathione deficit during development: Effect on lipid peroxidation in the rat brain. J Neurosci Res. 2002;70:774\u201383.","journal-title":"J Neurosci Res"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.3390\/ijm2212617","volume":"22","author":"MA Lech","year":"2021","unstructured":"Lech MA, Le\u015bkiewicz M, Kami\u0144ska K, Rog\u00f3\u017c Z, Lorenc-Koci E. Glutathione deficiency during early postnatal development caused schizophrenia-like symptoms and a reduction in BDNF levels in the cortex and hippocampus of adult Sprague-Dawley rats. Int J Mol Sci. 2021;22:6171. https:\/\/doi.org\/10.3390\/ijm2212617.","journal-title":"Int J Mol Sci"},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"KQ Do","year":"2009","unstructured":"Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19:220\u201330.","journal-title":"Curr Opin Neurobiol"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","volume":"35","author":"BK Bitanihirwe","year":"2011","unstructured":"Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/brainsci13030490","volume":"13","author":"M Wiedlocha","year":"2023","unstructured":"Wiedlocha M, Zborowska N, Marcinowicz P, Debowska W, Debowska M, Zalewska A, et al. Oxidative stress biomarkers among schizophrenia inpatients. Brain Sci. 2023;13:490. https:\/\/doi.org\/10.3390\/brainsci13030490.","journal-title":"Brain Sci"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"673002","DOI":"10.3389\/fgene.2021.673002","volume":"12","author":"SG Martins","year":"2021","unstructured":"Martins SG, Zilh\u00e3o R, Thorsteinsd\u00f3ttir S, Carlos AR. Linking oxidative stress and DNA damage to changes in the expression of extracellular matrix components. Front Genet. 2021;12:673002. https:\/\/doi.org\/10.3389\/fgene.2021.673002.","journal-title":"Front Genet"},{"key":"853_CR32","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","volume":"97","author":"K Jomova","year":"2023","unstructured":"Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol. 2023;97:2499\u2013574. https:\/\/doi.org\/10.1007\/s00204-023-03562-9.","journal-title":"Arch Toxicol"},{"key":"853_CR33","doi-asserted-by":"publisher","unstructured":"Cummings MA, Arias AW, Stahl SM. What is the neurobiology of schizophrenia? CNS Spectr. 2024 30:1\u20136. https:\/\/doi.org\/10.1017\/s1092852924000518","DOI":"10.1017\/s1092852924000518"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2183\/pjab.95.01","volume":"95","author":"K Obi-Nagata","year":"2019","unstructured":"Obi-Nagata K, Temma Y, Hayashi-Takagi A. Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model. Proc Jpn Acad Ser B Phys Biol Sci. 2019;95:179\u201397. https:\/\/doi.org\/10.2183\/pjab.95.01.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"2","key":"853_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrn.2015.19","volume":"17","author":"GE Hardingham","year":"2016","unstructured":"Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci. 2016;17(2):125\u201334.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"853_CR36","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1523\/JNEUROSCI.5485-09.2010","volume":"30","author":"K Bodhinathan","year":"2010","unstructured":"Bodhinathan K, Kumar A, Foster C. Intracellular redox state alters NMDA receptor response during aging through Ca2+\/calmodulin-dependent protein kinase II. J Neurosci. 2010;30(5):1914\u201324. https:\/\/doi.org\/10.1523\/JNEUROSCI.5485-09.2010.","journal-title":"J Neurosci"},{"key":"853_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pnpbp.2018.08.006","volume":"20","author":"TK Das","year":"2019","unstructured":"Das TK, Javadzadeh A, Dey A, Sabesan P, Th\u00e9berge J, Radua J, Palaniyappan L. Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. Prog Neuropsychopharmacol Biol Psychiatry. 2019;20:94\u2013102. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.08.006.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","volume":"12","author":"KQ Do","year":"2000","unstructured":"Do KQ, Trabesinger AH, Kirsten-Kr\u00fcger M, Lauer CJ, Dydak U, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721\u201328.","journal-title":"Eur J Neurosci"},{"issue":"4","key":"853_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.biopsych.2020.03.016","volume":"88","author":"DO Perkins","year":"2020","unstructured":"Perkins DO, Jeffries CD, Do KQ. Potential roles of redox dysregulation in the development of schizophrenia. Biol Psychiatry. 2020;88(4):326\u201336. https:\/\/doi.org\/10.1016\/j.biopsych.2020.03.016.","journal-title":"Biol Psychiatry"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"1255263","DOI":"10.1126\/science.1255263","volume":"345","author":"H Hu","year":"2014","unstructured":"Hu H, Gan J, Jonas P. Fast-spiking, parvalbumin (+) GABAergic interneurons: from cellular design to microcircuit function. Science. 2014;345:1255263.","journal-title":"Science"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"9130","DOI":"10.1073\/pnas.1300454110","volume":"110","author":"JH Cabungcal","year":"2013","unstructured":"Cabungcal JH, Steullet P, Morishita H, Kraftsik R, Cu\u00e9nod M, et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Natl acad Sci USA. 2013;110:9130\u201335.","journal-title":"Proc Natl acad Sci USA"},{"issue":"12","key":"853_CR42","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/bph.13425","volume":"174","author":"J Haslund-Vinding","year":"2017","unstructured":"Haslund-Vinding J, McBean G, Jaquet V, Vilhardt F. NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease. Br J Pharmacol. 2017;174(12):1733\u201349. https:\/\/doi.org\/10.1111\/bph.13425.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"853_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/mp.2014.88","volume":"20","author":"A Monin","year":"2015","unstructured":"Monin A, Baumann PS, Griffa A, Xin L, Mekle R, et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry. 2015;20(7):827\u201338. https:\/\/doi.org\/10.1038\/mp.2014.88.","journal-title":"Mol Psychiatry"},{"key":"853_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0165-1781(00)00230-4","volume":"97","author":"JK Yao","year":"2000","unstructured":"Yao JK, Reddy RD, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000;97:137\u201351.","journal-title":"Psychiatry Res"},{"key":"853_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000077942","volume":"50","author":"CU Pae","year":"2004","unstructured":"Pae CU, Palk IH, Lee, Lee SJ, Kim JJ, Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology. 2004;50:54\u20136.","journal-title":"Neuropsychobiology"},{"key":"853_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0165-1781(98)00051-1","volume":"80","author":"JK Yao","year":"1998","unstructured":"Yao JK, Reddy RD, van Cammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80:29\u201339.","journal-title":"Psychiatry Res"},{"key":"853_CR47","doi-asserted-by":"crossref","unstructured":"Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-na\u00efve patients with schizophrenia. Plos One 2010 5:e9508.","DOI":"10.1371\/journal.pone.0009508"},{"key":"853_CR48","first-page":"8057","volume":"32","author":"DS Abdella","year":"1986","unstructured":"Abdella DS, Monteiro HP, Olivera JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem. 1986;32:8057.","journal-title":"Clin Chem"},{"key":"853_CR49","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1042\/bst025418s","volume":"25","author":"NS Khan","year":"1997","unstructured":"Khan NS, Das TK. Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans. 1997;25:4185.","journal-title":"Biochem Soc Trans"},{"key":"853_CR50","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.pnpbp.2009.06.018","volume":"33","author":"M Raffa","year":"2009","unstructured":"Raffa M, Mechri A, Othman LB. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1178\u201383. Fendri C, Gaha I, Kerkeni A.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"853_CR51","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0006-3223(90)90061-6","volume":"28","author":"K Suboticanec","year":"1990","unstructured":"Suboticanec K, Folnegovic-Smalc V, Korbal M, Mestrovic B, Buzina R. Vitamine C status in chronic shizophrenia. Biol Psychiatry. 1990;28:959\u201366.","journal-title":"Biol Psychiatry"},{"key":"853_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000202823","volume":"59","author":"BM Al-Chalabi","year":"2009","unstructured":"Al-Chalabi BM, Thanoon IA, Ahmed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology. 2009;59:8\u201311.","journal-title":"Neuropsychobiology"},{"issue":"5116","key":"853_CR53","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.8100368","volume":"260","author":"M Zhuo","year":"1993","unstructured":"Zhuo M, Small SA, Kandel ER, Hawkins RD. Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science. 1993;260(5116):1946\u201350. https:\/\/doi.org\/10.1126\/science.8100368.","journal-title":"Science"},{"issue":"3","key":"853_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0959-4388(99)80045-2","volume":"9","author":"RS Zucker","year":"1999","unstructured":"Zucker RS. Calcium- and activity-dependent synaptic plasticity. Curr Opin Neurobiol. 1999;9(3):305\u201313. https:\/\/doi.org\/10.1016\/s0959-4388(99)80045-2.","journal-title":"Curr Opin Neurobiol"},{"key":"853_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0074-7742(04)59011-6","volume":"59","author":"D Ben-Shachar","year":"2004","unstructured":"Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol. 2004;59:273\u201396. https:\/\/doi.org\/10.1016\/S0074-7742(04)59011-6.","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"853_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/157015911795596504","volume":"9","author":"I B\u00f3kkon","year":"2011","unstructured":"B\u00f3kkon I, Anta I. Schizophrenia: redox regulation and volume neurotransmission. Curr Neuropharmacol. 2011;9(2):289\u2013300.","journal-title":"Curr Neuropharmacol"},{"key":"853_CR57","first-page":"237","volume":"23","author":"A Ciobica","year":"2011","unstructured":"Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr Danub. 2011;23:237\u201345.","journal-title":"Psychiatr Danub"},{"key":"853_CR58","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1089\/ars.2010.3603","volume":"15","author":"JK Yao","year":"2011","unstructured":"Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011\u201335.","journal-title":"Antioxid Redox Signal"},{"key":"853_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1461145710000805","volume":"14","author":"JW Gawryluk","year":"2011","unstructured":"Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of gluthatione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"853_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1155\/2006\/248387","volume":"22","author":"JK Yao","year":"2006","unstructured":"Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22:83\u201393.","journal-title":"Dis Markers"},{"key":"853_CR61","doi-asserted-by":"publisher","first-page":"896694","DOI":"10.3389\/fpsyt.2022.896694","volume":"13","author":"M Yang","year":"2022","unstructured":"Yang M, Li J, Yang H, Yan L, Liu D, Zhu L, et al. Cognitive impairment and psychopathology are related to plasma oxidative stress in long term hospitalized patients with chronic schizophrenia. Front Psychiatry. 2022;13:896694. https:\/\/doi.org\/10.3389\/fpsyt.2022.896694.","journal-title":"Front Psychiatry"},{"key":"853_CR62","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","volume":"3","author":"D Matsuzawa","year":"2008","unstructured":"Matsuzawa D, Obata T, ShirayamaY, Nonaka H, Kanazawa Y, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a3T IH-MRS study. PLoS ONE. 2008;3:e1944.","journal-title":"PLoS ONE"},{"key":"853_CR63","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1086\/507566","volume":"79","author":"M Tosic","year":"2006","unstructured":"Tosic M, Ott J, Barral S, Bovet P, Deppen P, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet. 2006;79:586\u201392.","journal-title":"Am J Hum Genet"},{"key":"853_CR64","doi-asserted-by":"publisher","first-page":"16621","DOI":"10.1073\/pnas.0706778104","volume":"104","author":"R Gysin","year":"2007","unstructured":"Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA. 2007;104:16621\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"853_CR65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.brainresbull.2008.10.015","volume":"79","author":"R Gysin","year":"2009","unstructured":"Gysin R, Riederer IM, Cu\u00e9nod M, Do KQ, Riederer BM. Skin fibroblast model to study an impaired glutathione synthesis: consequences of a genetic polymorphism on the proteome. Brain Res Bull. 2009;79:46\u201352.","journal-title":"Brain Res Bull"},{"key":"853_CR66","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1089\/ars.2010.3463","volume":"15","author":"R Gysin","year":"2011","unstructured":"Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15:2003\u201310.","journal-title":"Antioxid Redox Signal"},{"key":"853_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0920-9964(95)00048-8","volume":"19","author":"S Mukerjee","year":"1996","unstructured":"Mukerjee S, MahadikSP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res. 1996;19:19\u201326.","journal-title":"Schizophr Res"},{"key":"853_CR68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.plefa.2003.08.010","volume":"69","author":"DR Evans","year":"2003","unstructured":"Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leucot Essent Fat Acids. 2003;69:393\u201399.","journal-title":"Prostaglandins Leucot Essent Fat Acids"},{"key":"853_CR69","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-244X-11-124","volume":"1","author":"M Raffa","year":"2011","unstructured":"Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry. 2011;1:124.","journal-title":"BMC Psychiatry"},{"key":"853_CR70","doi-asserted-by":"crossref","unstructured":"Mic\u00f3 JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, Moreno D, et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMS Psychiatry. 2011;11:26.","DOI":"10.1186\/1471-244X-11-26"},{"key":"853_CR71","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/clinchem\/32.5.805","volume":"32","author":"DS Abdalla","year":"1986","unstructured":"Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem. 1986;32:805\u20137.","journal-title":"Clin Chem"},{"key":"853_CR72","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1515\/CCLM.2000.201","volume":"38","author":"I Altuntas","year":"2000","unstructured":"Altuntas I, Aksoy H, Coskun I, Cayk\u00f6yl\u00fc A, Akcaay F. Erythrocyte superoxidedismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med. 2000;38:1277\u201381.","journal-title":"Clin Chem Lab Med"},{"key":"853_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0165-1781(03)00220-8","volume":"121","author":"PK Ranjekar","year":"2003","unstructured":"Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, et al. Decrease antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109\u201322.","journal-title":"Psychiatry Res"},{"key":"853_CR74","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.schres.2005.10.011","volume":"81","author":"XY Zhang","year":"2006","unstructured":"Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81:291\u2013300.","journal-title":"Schizophr Res"},{"key":"853_CR75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pnpbp.2007.08.003","volume":"32","author":"L Ben Othmen","year":"2008","unstructured":"Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected sibling. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:155\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"853_CR76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0006-3223(91)90298-Z","volume":"30","author":"R Reddy","year":"1991","unstructured":"Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry. 1991;30:409\u201312.","journal-title":"Biol Psychiatry"},{"key":"853_CR77","doi-asserted-by":"crossref","unstructured":"Herken H, UZ E, Ozyurt H, S\u00f6g\u00fct S, Virit O, Akyol O. Evidence of the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased indifferent forms of schizophrenia. Mol Psychiatry. 2001;66\u201373.","DOI":"10.1038\/sj.mp.4000789"},{"key":"853_CR78","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0278-5846(02)00220-8","volume":"26","author":"O Akyol","year":"2002","unstructured":"Akyol O, Herken H, Uz E, Fadillo\u011flu E, Unal S, et al. The indicates of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant\/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:995\u20131005.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"853_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0920-9964(02)00405-x","volume":"62","author":"G Grima","year":"2003","unstructured":"Grima G, Benz B, Parpura V, Cu\u00e9nod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res. 2003;62(3):213\u201324. https:\/\/doi.org\/10.1016\/s0920-9964(02)00405-x.","journal-title":"Schizophr Res"},{"issue":"26","key":"853_CR80","doi-asserted-by":"publisher","first-page":"15420","DOI":"10.1074\/jbc.271.26.15420","volume":"271","author":"DJ Van den Dobbelsteen","year":"1996","unstructured":"Van den Dobbelsteen DJ, Nobel CS, Schlegel J, Cotgreave IA, Orrenius S, Slater AF. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas\/APO-1 antibody. J Biol Chem. 1996;271(26):15420\u20137. https:\/\/doi.org\/10.1074\/jbc.271.26.15420.","journal-title":"J Biol Chem"},{"issue":"6","key":"853_CR81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1096\/fasebj.12.6.479","volume":"12","author":"L Ghibelli","year":"1998","unstructured":"Ghibelli L, Fanelli C, Rotilio G, Lafavia E, Coppola S, et al. Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J. 1998;12(6):479\u201386. https:\/\/doi.org\/10.1096\/fasebj.12.6.479.","journal-title":"FASEB J"},{"key":"853_CR82","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.neuroscience.2003.11.012","volume":"123","author":"V Castagn\u00e9","year":"2004","unstructured":"Castagn\u00e9 V, Cu\u00e9nod M, Do KQ. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in Osteogenic Disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience. 2004;123:821\u201334.","journal-title":"Neuroscience"},{"key":"853_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nbd.2003.09.005","volume":"15","author":"V Castagn\u00e9","year":"2004","unstructured":"Castagn\u00e9 V, Rougemont M, Cu\u00e9nod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat\u2019s development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis. 2004;15:93\u2013105.","journal-title":"Neurobiol Dis"},{"key":"853_CR84","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nbd.2006.01.003","volume":"22","author":"JH Cabungcal","year":"2006","unstructured":"Cabungcal JH, Nicolas D, Kraftsik R, Cu\u00e9nod M, Do KQ, Hornung J-P. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis. 2006;22:624\u201337.","journal-title":"Neurobiol Dis"},{"key":"853_CR85","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","volume":"52","author":"A Meister","year":"1983","unstructured":"Meister A, Anderson ME, Glutathione. Annu Rev Biochem. 1983;52:711\u201360.","journal-title":"Annu Rev Biochem"},{"key":"853_CR86","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1523\/JNEUROSCI.19-02-00562.1999","volume":"19","author":"R Dringen","year":"1999","unstructured":"Dringen R, Pfeiffer B, Hamprecht B. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGlu as precursor for neuronal glutathione. J Neurosci. 1999;19:562\u201359.","journal-title":"J Neurosci"},{"key":"853_CR87","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1016\/S0021-9258(17)42728-1","volume":"259","author":"JD Finkelstei","year":"1984","unstructured":"Finkelstei JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem. 1984;259:9508\u201313.","journal-title":"J Biol Chem"},{"key":"853_CR88","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0021-9258(17)35979-3","volume":"261","author":"JD Finkelstei","year":"1986","unstructured":"Finkelstei JD, Martin JJ. Methionine metabolism in mammals. Adaptation to methionine excess. J Biol Chem. 1986;261:1582\u20137.","journal-title":"J Biol Chem"},{"key":"853_CR89","doi-asserted-by":"publisher","first-page":"35785","DOI":"10.1074\/jbc.M602799200","volume":"281","author":"V Vitvitsky","year":"2006","unstructured":"Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Benerjee R. A functional transsulfuration. Pathway in the brain links to glutathione homeostasis. J Biol Chem. 2006;281:35785\u201393.","journal-title":"J Biol Chem"},{"key":"853_CR90","first-page":"51694","volume":"45","author":"JD Finkelstei","year":"2007","unstructured":"Finkelstei JD. Metabolic regulatory properties of S-adenosyl methionine and S-adenosylhomocysteine. Clin Chem Lab Med. 2007;45:51694\u201399.","journal-title":"Clin Chem Lab Med"},{"key":"853_CR91","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","volume":"1830","author":"SC Lu","year":"2013","unstructured":"Lu SC. Glutathione synthesis. Biochem Biophys Acta. 2013;1830:3143\u201353.","journal-title":"Biochem Biophys Acta"},{"key":"853_CR92","first-page":"209","volume":"8","author":"SM Cohen","year":"1974","unstructured":"Cohen SM, Nichols A, Wyatt R, Pollin W. The administration of methionine to chronic schizophrenic patients: A review of ten studies. Biol Psychiatry. 1974;8:209\u201325.","journal-title":"Biol Psychiatry"},{"key":"853_CR93","doi-asserted-by":"publisher","first-page":"17095","DOI":"10.1073\/pnas.262658999","volume":"99","author":"L Tremolizzo","year":"2002","unstructured":"Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia volunerability. Proc Natl Acad Sci USA. 2002;99:17095\u2013100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"853_CR94","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.biopsych.2004.11.046","volume":"57","author":"L Tremolizzo","year":"2005","unstructured":"Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry. 2005;57:500\u20139.","journal-title":"Biol Psychiatry"},{"key":"853_CR95","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.0505394102","volume":"102","author":"E Dong","year":"2005","unstructured":"Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A. Reelin and glutamic acid decarboxylase67 promotor remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci USA. 2005;102:12578\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"853_CR96","first-page":"1","volume":"18","author":"L Wang","year":"2015","unstructured":"Wang L, Alachkar A, Sanathara N, Belluzzi JD, Wang Z, Civelli OA. A methionine-induced animal model of schizophrenia. Face and prodictive validity. Int J Neuropsychpharmacol. 2015;18:1\u201311.","journal-title":"Int J Neuropsychpharmacol"},{"key":"853_CR97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-319-53889-1_12","volume":"978","author":"LK Pries","year":"2017","unstructured":"Pries LK, G\u00fcl\u00f6ks\u00fcs S, Kenis G. DNA methylation in schizophrenia. Adv Exp Med Biol. 2017;978:211\u201336.","journal-title":"Adv Exp Med Biol"},{"key":"853_CR98","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ymgme.2014.10.006","volume":"113","author":"PR Mandaviya","year":"2014","unstructured":"Mandaviya PR, Stolk L, Heil SG. Homocysteine and DNA methylation. A review of animal and human literature. Mol Genet Metab. 2014;113:243\u201352.","journal-title":"Mol Genet Metab"},{"key":"853_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.aninu.2017.08.009","volume":"4","author":"N Zhang","year":"2018","unstructured":"Zhang N. Role of methionine on epigenetic modification of DNA methylation and gene expression in animals. Anim Nutr. 2018;4:11\u20136.","journal-title":"Anim Nutr"},{"key":"853_CR100","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"18","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris N, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;18:419\u201332.","journal-title":"Pharmacol Ther"},{"key":"853_CR101","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","volume":"20","author":"L Rajagopal","year":"2014","unstructured":"Rajagopal L, Masse BW, Huang M, Oyamada Y, Meltzer HY. The novel object recognition test in rodents in relative to cognitive impairment in schizophrenia. Curr Pharm Des. 2014;20:5104\u201314.","journal-title":"Curr Pharm Des"},{"key":"853_CR102","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.euroneuro.2004.12.005","volume":"5","author":"G Shoval","year":"2005","unstructured":"Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol. 2005;5:319\u201329.","journal-title":"Eur Neuropsychopharmacol"},{"key":"853_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"P Steullet","year":"2016","unstructured":"Steullet P, Cabungcal JH, Monin A, Dwi D, O\u2019Donnell P, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A central hub in schizophrenia pathophysiology? Schizophr Res. 2016;176:41\u201351.","journal-title":"Schizophr Res"},{"key":"853_CR104","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0893-133X(00)00137-8","volume":"23","author":"BK Lipska","year":"2000","unstructured":"Lipska BK, Weinberger DR. To model a psyciatric disorder in animals. Schizophrenia as a reality test. Neuropsychopharmacology. 2000;23:223\u201339.","journal-title":"Neuropsychopharmacology"},{"key":"853_CR105","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0006-8993(02)03176-1","volume":"956","author":"P Ashe","year":"2002","unstructured":"Ashe P, Chlan-Fourney J, Juorio AV, Li XM. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res. 2002;956:126\u201335.","journal-title":"Brain Res"},{"key":"853_CR106","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1460-9568.2004.03592.x","volume":"20","author":"F Fumagalli","year":"2004","unstructured":"Fumagalli F, Bedogni F, Perez J, Racagni G, Riva MA. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci. 2004;20:1348\u201354.","journal-title":"Eur J Neurosci"},{"key":"853_CR107","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.biopsych.2003.12.011","volume":"55","author":"M Roceri","year":"2004","unstructured":"Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derivd neurotrophic factor expression in selected rat brain regions. Biol Psychiatry. 2004;55:708\u201314.","journal-title":"Biol Psychiatry"},{"key":"853_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2007.01.025","volume":"94","author":"PF Buckley","year":"2007","unstructured":"Buckley PF, Mahadik S, Pillai A, Terry A. Jr. Neurotrophins and schizophrenia. Schizophr Res. 2007;94:1\u201311.","journal-title":"Schizophr Res"},{"key":"853_CR109","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s43440-021-00318-z","volume":"73","author":"MA Lech","year":"2021","unstructured":"Lech MA, Kami\u0144ska K, Le\u015bkiewicz M, Lorenc-Koci E, Rog\u00f3\u017c Z. Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats expressed to glutathione deficit during early postnatal development of the brain. Pharmacol Rep. 2021;73:1712\u201323.","journal-title":"Pharmacol Rep"},{"key":"853_CR110","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.pharep.2017.02.022","volume":"69","author":"Z Rog\u00f3\u017c","year":"2017","unstructured":"Rog\u00f3\u017c Z, Kami\u0144ska K, Pa\u0144czyszyn-Trzewik P, Sowa-Ku\u0107ma M. Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats. Pharmacol Rep. 2017;69:885\u201393.","journal-title":"Pharmacol Rep"},{"key":"853_CR111","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2010.06.028","volume":"643","author":"S Alboni","year":"2010","unstructured":"Alboni S, Benatti C, Capone G, Corsin D, Caggia F, et al. Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats. Eur J Pharmacol. 2010;643:180\u20137.","journal-title":"Eur J Pharmacol"},{"key":"853_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","volume":"80","author":"A Luoni","year":"2014","unstructured":"Luoni A, Fumagalli F, Racagni G, Riva MA. Repeated aripiprazole treatment regulate Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the brain. Pharmacol Res. 2014;80:1\u20138.","journal-title":"Pharmacol Res"},{"key":"853_CR113","first-page":"699","volume":"72","author":"MA Lech","year":"2021","unstructured":"Lech MA, Kami\u0144ska K, W\u0105sik A, Lorenc-Koci E, Rog\u00f3\u017c Z. Repeated co-treatment with mirtazapine and aripiprazole reversed the schizophrenia\u2013like behaviors and increased the brain-derived neurotrophic factor mRNA expression in the adult Sprague-Dawley rats expressed to glutathione deficit during early postnatal brain l development. J Physiol Pharmacol. 2021;72:699\u2013709.","journal-title":"J Physiol Pharmacol"},{"key":"853_CR114","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.brainres.2016.07.042","volume":"1648","author":"D Preissmann","year":"2016","unstructured":"Preissmann D, D\u00e9pr\u00e9 M, Schenk F, Gisquet-Verrier P. Anxiety modulates cognitive deficits in a perinatal glutathione deficit animal model of schizophrenia. Brain Res. 2016;1648:459\u201368.","journal-title":"Brain Res"},{"key":"853_CR115","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1046\/j.1471-4159.2003.01580.x","volume":"84","author":"SA Farr","year":"2003","unstructured":"Farr SA, Poon GF, Dogrukol-Ak D, Drake J, Banks WA, et al. The antioxidants alpha-lipoic acid and N-acetylcysteina reverse memory impairment and brain oxidative stress in agent SAMP8 mice. J Neurochem. 2003;84:1173\u201383.","journal-title":"J Neurochem"},{"key":"853_CR116","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-0609.1996.tb01370.x","volume":"57","author":"D Mazor","year":"1996","unstructured":"Mazor D, Golan E, Philip V, Katz M, Jafe A, et al. Red blood cell perme ability to thiol compounds following oxidative stress. Eur J Haematol. 1996;57:241\u201346.","journal-title":"Eur J Haematol"},{"key":"853_CR117","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.100057","volume":"36","author":"O Dean","year":"2011","unstructured":"Dean O, Giorlando F, Beck M. N-acetylocysteine in psychiatry: Current therapeutic evidence and potential mechanism of action. J Psychiatry Neurosci. 2011;36:78\u201386.","journal-title":"J Psychiatry Neurosci"},{"key":"853_CR118","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0891-5849(89)90066-X","volume":"66","author":"OI Aruoma","year":"1989","unstructured":"Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;66:593\u201397.","journal-title":"Free Radic Biol Med"},{"key":"853_CR119","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0197-0186(95)00114-X","volume":"29","author":"S Hussain","year":"1996","unstructured":"Hussain S, Slikker WJR, Ali SF. Role of metallothionein and other antioxidants in scaveringing superoxide radicals and thewir possible role in neuroprotection. Neurochem Int. 1996;29:145\u201352.","journal-title":"Neurochem Int"},{"key":"853_CR120","doi-asserted-by":"publisher","unstructured":"Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L et al. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021; 11;19(8):1202\u20131224. https:\/\/doi.org\/10.2174\/1570159X19666201230144109","DOI":"10.2174\/1570159X19666201230144109"},{"issue":"6","key":"853_CR121","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/schbul\/sbac065","volume":"48","author":"E Neill","year":"2022","unstructured":"Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, et al. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double-blind, randomized, placebo-controlled trial argeting negative symptoms. Schizophr Bull. 2022;48(6):1263\u201372. https:\/\/doi.org\/10.1093\/schbul\/sbac065.","journal-title":"Schizophr Bull"},{"issue":"2","key":"853_CR122","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pcn.13502","volume":"77","author":"T Kishi","year":"2023","unstructured":"Kishi T, Sakuma K, Hatano M. N-acetylcysteine for schizophrenia: Asystematic review and meta-analysis. Psychiatry Clin Neurosci. 2023;77(2):119\u201321. https:\/\/doi.org\/10.1111\/pcn.13502. ,Iwata N.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"853_CR123","doi-asserted-by":"publisher","first-page":"e2880","DOI":"10.1002\/hup.2880","volume":"39","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Liu Z, Wang T, Yu M, Li X. Efficacy and acceptability of adjunctive N-acetylcysteine for psychotic disorders: Systematic review and meta-analysis. Hum Psychopharmacol. 2024;39(2):e2880. https:\/\/doi.org\/10.1002\/hup.2880.","journal-title":"Hum Psychopharmacol"},{"key":"853_CR124","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673365458250901115725","author":"D Marazziti","year":"2025","unstructured":"Marazziti D, Caruso V, Cappellato G, Chiarantini I, Gurrieri R, Perrone P, et al. The emerging role of N-acetylcysteine in Psychiatry: A narrative review of available data. Curr Med Chem. 2025. https:\/\/doi.org\/10.2174\/0109298673365458250901115725.","journal-title":"Curr Med Chem"},{"key":"853_CR125","doi-asserted-by":"publisher","first-page":"110527","DOI":"10.1016\/j.neuropharm.2025.110527","volume":"278","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Shankaranarayana Rao BS, Tripathi SJ. The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders From modulation of glutamatergic transmission to restoration of synaptic plasticity. Neuropharmacology. 2025;278:110527. https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110527.","journal-title":"Neuropharmacology"},{"key":"853_CR126","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu K, Jeavons S, et al. N-acetylcysteine as a glutathione precursor for schizophrenia-adouble-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361\u201368.","journal-title":"Biol Psychiatry"},{"key":"853_CR127","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu K, Jeavons S, et al. N-acetylcysteinefor depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468\u201375.","journal-title":"Biol Psychiatry"},{"key":"853_CR128","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","volume":"33","author":"S Lavoie","year":"2008","unstructured":"Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, et al. Glutathione precursor, N-acetyl-cysteine, improveds mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33:2187\u201399.","journal-title":"Neuropsychopharmacology"},{"key":"853_CR129","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/1028415X.2018.1478766","volume":"23","author":"COB Yolland","year":"2020","unstructured":"Yolland COB, Phillipou A, Castle DJ, Nell E, Hughes ME, et al. Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. Nutr Neurosci. 2020;23:139\u201348.","journal-title":"Nutr Neurosci"},{"key":"853_CR130","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1742-1241.2003.tb11397.x","volume":"57","author":"DM Taylor","year":"2003","unstructured":"Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57:49\u201354.","journal-title":"Int J Clin Pract"},{"key":"853_CR131","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DS Shapiro","year":"2003","unstructured":"Shapiro DS, Renock S, Arrington E, Chiodo LA, Liu L. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"853_CR132","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","volume":"493","author":"Z Li","year":"2004","unstructured":"Li Z, Ichikawa J, Dai J, Meltze HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493:75\u201383.","journal-title":"Eur J Pharmacol"},{"key":"853_CR133","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"44","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottor K, Kikuchi T, Altar A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;44:137\u201340.","journal-title":"Eur J Pharmacol"},{"key":"853_CR134","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.neuropharm.2011.08.031","volume":"62","author":"S Tanahashi","year":"2012","unstructured":"Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. 2012;62:765\u201374.","journal-title":"Neuropharmacology"},{"key":"853_CR135","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML. Aripiprazole, a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649\u201366.","journal-title":"Clin Ther"},{"issue":"24","key":"853_CR136","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1111\/febs.16944","volume":"290","author":"M G\u00f3rny","year":"2023","unstructured":"G\u00f3rny M, Bilska-Wilkosz A, Iciek M, Rog\u00f3\u017c Z, Lorenc-Koci E. Treatment with aripiprazple and N-acetylcysteine affects anaerobic cysteine metabolizm in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. FEBS J. 2023;290(24):5773\u201393.","journal-title":"FEBS J"},{"key":"853_CR137","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/ijms23042125","volume":"23","author":"Z Rog\u00f3\u017c","year":"2022","unstructured":"Rog\u00f3\u017c Z, Kami\u0144ska K, Lech MA, Lorenc-Koci E. N-Acetylcysteine and aripiprazole improve social behavior and cognition and modulate brain BDNF levels in a rat model of schizophrenia. Int J Mol Sci. 2022;23:2125. https:\/\/doi.org\/10.3390\/ijms23042125.","journal-title":"Int J Mol Sci"},{"key":"853_CR138","doi-asserted-by":"publisher","first-page":"174028","DOI":"10.1016\/j.pbb.2025.174028","volume":"252","author":"Z Rog\u00f3\u017c","year":"2025","unstructured":"Rog\u00f3\u017c Z, Kami\u0144ska K, W\u0105sik A. N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia. Pharmacol Biochem Behav. 2025;252:174028. https:\/\/doi.org\/10.1016\/j.pbb.2025.174028.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"853_CR139","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1192\/j.eurpsy.20","volume":"18","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;18(1):64. https:\/\/doi.org\/10.1192\/j.eurpsy.20.","journal-title":"Eur Psychiatry"},{"key":"853_CR140","doi-asserted-by":"publisher","unstructured":"Zhang K, Zou L, Cai Y. Progress in the study of oxidative stress damage in patients with schizophrenia: challenges and opportunities. Front Psychiatry. 2025;16:1505397. https:\/\/doi.org\/10.3389\/fpsyt.2025.1505397. eCollection 2025.","DOI":"10.3389\/fpsyt.2025.1505397"},{"issue":"7\u20138","key":"853_CR141","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s12031-023-02140-z","volume":"73","author":"AS Piatoikina","year":"2023","unstructured":"Piatoikina AS, Zhilyaeva TV, Kostina OV, Zhukova ES, Shcherbatyuk TG, Mazo GE. Gender-related Characteristics of Oxidative Stress Severity and Cognitive Impairment in Patients With Schizophrenia. J Mol Neurosci. 2023;73(7\u20138):628\u201334. https:\/\/doi.org\/10.1007\/s12031-023-02140-z.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"853_CR142","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12974-021-02261-5","volume":"18","author":"M Zhu","year":"2021","unstructured":"Zhu M, Liu Z, Guo Y, Sultana MS, Wu K, Lang X, Lv Q, Huang X, Yi Z, Li ZJ. Sex difference in the interrelationship between TNF-\u03b1 and oxidative stress status in first-episode drug-na\u00efve schizophrenia. Neuroinflammation. 2021;18(1):202. https:\/\/doi.org\/10.1186\/s12974-021-02261-5.","journal-title":"Neuroinflammation"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00853-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:04:58Z","timestamp":1781687098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00853-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00853-7","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript and tables have been proofread using \u201cGrammarly\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}